I care about your Barrett’s esophagus (BE), because it is a reflux induced tissue with malignant potential.
Barrett’s esophagus (BE) develops as a consequence of gastric acid reflux (gastroesophageal reflux) and harbours a 0.5% - 1.7% annual cancer risk. This means, that 1-2 out of 10 individuals with Barrett’s esophagus may develop oesophageal cancer in 20 years.
In fact the frequency of oesophageal cancer dramatically increased in the last 40 years. 40 years ago we had about 30 new cases of reflux cancer of the esophagus per year in 1980. Today we collect about 700 new cases per year in Austria.
Recent evidence indicates, that in 2030, 1 out of 100 men in Europe or North America (USA) will develop reflux induced oesophageal cancer of the esophagus during their life time (Arnold M; Am J Gastro 2017; 112: 1247-55).
The diagnosis of Barrett’s esophagus (BE) is established by the histopathology of biopsies obtained from the esophagus.
According to the novel US American Chandrasoma classification we list:
Barrett’s esophagus (BE) without dysplasia (= less severe tissue change)
Barrett’s esophagus (BE) with dysplasia (=severe tissue change)
Barrett’s esophagus with dysplasia may progress to esophageal cancer (0.5% - 1.7% annual risk).
I offer cancer prevention by:
early cancer risk assessment (endoscopy, histopathology; Chandrasoma classification)
elimination of cancer risk tissue (radiofrequency ablation, RFA)
treatment of the cause of BE, i.e. elimination of reflux, using nutrition ± laparoscopic anti reflux surgery
regular follow up tests to exclude recurrence of BE and cancer risk.